The PRISMA flow diagram of the study is shown in Fig. 1. We found 129 articles related to the title of this study by search strategy, 8 of which were duplicates and were removed. We screened the titles and abstracts of 121 selected articles for eligibility, and 80 studies were excluded because they did not meet our inclusion and exclusion criteria. Forty-one studies were selected for full-text analysis; after their selection, 1 study was excluded because its data were incomplete or repeated, such as the results of other included articles (the same authors). Finally, 40 case‒control studies were included in the systematic review. Among these selected studies, 20 studies investigated the effect of DOX in melanoma, 17 studies investigated the effect of CAP in the treatment of melanoma, and 3 studies investigated the simultaneous relationship between CAP and DOX in melanoma.
The level of cell viability in these studies was mostly measured via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the degree of cell cytotoxicity was mostly measured via annexin flow cytometry. In these studies, cell death was mostly measured via the assessment of the propidium iodide (PI). Egger’s test did not indicate any evidence of publication bias. All included studies were moderate- to high-quality (14 high-quality studies and 26 moderate-quality studies). The characteristics of the included studies are described in Table 1.
3.1. Main results of the meta-analysis
3.2.1. Meta-analysis of the association between melanoma cell viability and treatment: Pooled analysis of the 25 studies[18-37] investigated the association between melanoma cell viability and CAP treatment. The analysis of the dominant model indicated that a significant association existed between melanoma CAP treatment and decreased melanoma cell viability ([ES] = 58.16, 95% [CI]: 43.59--72.73, I2 = 94.1%). Moreover, 18 studies[28, 38-55] investigated the association between melanoma cell viability and DOX treatment. The analysis of the dominant model indicated that a significant association existed between melanoma DOX treatment and decreased melanoma cell viability ([ES] = 23.96, 95% [CI]: 17.26--13.66, I2 = 86.1%). Six studies[22, 28, 34] investigated the associations between melanoma cell viability and CAP and DOX treatment. The analysis of the dominant model indicated that a significant association existed between melanoma CAP and DOX treatment and decreased melanoma cell viability ([ES] = 6.75, 95% [CI]: 1.65--11.85, I2 = 71%). (Fig. 2)
3.2.2. Meta-analysis of the association between melanoma cell death and treatment:
Seven studies[18, 19, 22-25, 28, 30] evaluated the association between melanoma cell death and CAP treatment. Overall, the results revealed a significant association between melanoma CAP treatment and increased melanoma cell death ([ES] = 3.95, 95% [CI]: 1.59--6.31, I2 = 68.1%). Moreover, in 10 studies[22, 28, 41, 47, 50, 51, 53, 56, 57], the association of melanoma cell death with DOX treatment was evaluated. DOX treatment was significantly associated with increased melanoma cell death ([ES] = 8.17, 95% [CI]: 3.71--12.64, I2 = 84.2%). Pooled analysis of the 3 studies[22, 28] investigated the associations between melanoma cell death and CAP and DOX treatment. The analysis of the dominant model indicated that an association existed between melanoma CAP and DOX treatment and increased melanoma cell death ([ES] = 2.14, 95% [CI]: -0.55--4.84, I2 = 71.0%) (Fig. 3)
3.2.3. Meta-analysis of the association between melanoma cell cytotoxicity and treatment:
In 12 studies[18-20, 22, 27, 28, 30, 33, 37], the association of melanoma cell cytotoxicity with CAP treatment was evaluated. Significant associations were found for CAP treatment and increased melanoma cell cytotoxicity ([ES] = 5.76, 95% [CI]: 2.80--8.73, I2 = 82.8%). In addition, no significant association was found between melanoma cell cytotoxicity and DOX[22, 28, 38, 39] treatment ([ES] = 7.27, 95% [CI]: 3.91--10.64, I2 = 0). Three studies[22, 28] evaluated the associations between melanoma cell cytotoxicity and CAP and DOX treatment. Overall, the results revealed a significant association between melanoma CAP and DOX treatment and increased melanoma cell death ([ES] = 11.71, 95% [CI]: 3.69--19.73, I2 = 56%) (Fig. 4)
Fig. 4. Association between melanoma training and cell cytotoxicity. (A) CAP treatment vs. cell cytotoxicity analysis. (B) DOX treatment vs. cell cytotoxicity analysis. (C) DOX-CAP treatment vs. cell cytotoxicity.
3.2. Subgroup and intragroup analyses:
Due to significant heterogeneity between studies, subgroup analyses were performed. The data related to the subgroup analyses of the studied studies are shown in Table 2). In addition, among the 3 studies that investigated the effects of CAP and DOX and used 5 different types of melanoma, intragroup analyses were performed. The analysis of the dominant model indicated that a significant association existed between melanoma cell viability and CAP treatment ([ES] = 82, 95% [CI]: 72.8--92.29, I2 = 62.7%) or DOX treatment ([ES] = 40.80% [CI]: 19.63--61.97, I2 = 85.6%). Intragroup analyses revealed that CAP treatment ([ES] = 1.21% [CI]: 0.09--2.33, I2 = 39%) and DOX treatment ([ES] = 1.35% [CI]: -3.82--6.52, I2 = 87.4%) are associated with melanoma cell death. Moreover, among the 3 studies, CAP treatment was significantly associated with increased melanoma cell cytotoxicity ([ES] = 1.84% [CI]: -1.14 to 4.09, I2 = 75%) (Figs. 5, 6).